Page last updated: 2024-12-08
quinoprazine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
quinoprazine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 159481 |
| CHEMBL ID | 494487 |
| SCHEMBL ID | 12851549 |
| MeSH ID | M0205230 |
Synonyms (24)
| Synonym |
|---|
| HMS1473C09 |
| benzo(g)quinolin-4-amine, n-(4-(4-ethyl-1-piperazinyl)phenyl)- |
| n-(4-(4-ethyl-1-piperazinyl)phenyl)benzo(g)quinolin-4-amine |
| quinoprazine |
| CBDIVE_004992 |
| OPREA1_224629 |
| CHEMDIV3_000053 |
| EU-0000010 |
| IDI1_019371 |
| NCGC00173873-01 |
| AKOS001483131 |
| 115618-99-0 |
| CHEMBL494487 |
| n-[4-(4-ethylpiperazin-1-yl)phenyl]benzo[g]quinolin-4-amine |
| STK525165 |
| 4-(4-(4-ethylpiperazinyl-1)phenylamino)benzo(g)quinoline |
| us9211296, table 7, compd: 1 |
| bdbm196131 |
| SCHEMBL12851549 |
| DTXSID10921777 |
| n-[4-(4-ethylpiperazin-1-yl)phenyl]benzo[g]quinolin-4(1h)-imine |
| n-(4-(4-ethylpiperazin-1-yl)phenyl)benzo[g]quinolin-4-amine |
| HY-147371 |
| CS-0567634 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (10)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1057860 | Cytotoxicity against mouse dividing ScN2a-cl3 cells assessed as cell viability at 10 uM after 5 days by calcein-AM staining-based fluorescence assay | 2013 | Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24 | Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells. |
| AID390739 | Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as protection from virus-induced lysis of cell monolayer up to 200 uM after 20 hrs | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20 | Identification of non-nucleoside DNA synthesis inhibitors of vaccinia virus by high-throughput screening. |
| AID1057859 | Inhibition of RML prion protein infected in mouse stationary-phase ScN2a-cl3 cells expressing full length mouse PrP assessed as reduction of PrPsc level at 10 uM after 5 days by ELISA | 2013 | Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24 | Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells. |
| AID1057865 | Inhibition of RML prion protein infected in mouse dividing ScN2a-cl3 cells expressing full length mouse PrP assessed as reduction of PrPsc level at 10 uM after 5 days by ELISA | 2013 | Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24 | Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells. |
| AID390738 | Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as reduction in plaque formation up to 200 uM after 20 hrs | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20 | Identification of non-nucleoside DNA synthesis inhibitors of vaccinia virus by high-throughput screening. |
| AID1057858 | Cytotoxicity against mouse stationary-phase ScN2a-cl3 cells assessed as cell viability at 10 uM after 5 days by calcein-AM staining-based fluorescence assay | 2013 | Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24 | Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells. |
| AID390731 | Inhibition of Vaccinia virus DNA synthesis in by rapid plate assay | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20 | Identification of non-nucleoside DNA synthesis inhibitors of vaccinia virus by high-throughput screening. |
| AID390740 | Cytotoxicity against african green monkey BSC1 cells up to 200 uM after 20 to 120 hrs WST-1 based assay | 2008 | Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20 | Identification of non-nucleoside DNA synthesis inhibitors of vaccinia virus by high-throughput screening. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||